Compare Cambria Cannabis ETF (TOKE) With Other Cannabis Stocks

Head-to-head stock comparisons across price, valuation, financials, and growth metrics

Company

Cambria Cannabis ETF (TOKE)

Price

$5.42

Change

0.00%

Market Cap

$16.0M

Sector

ETF

ETF Sector Peers

All ETF cannabis companies sorted by market capitalization. Click any ticker to see a detailed head-to-head comparison.

TickerNamePriceChange %MCap
MSOSAdvisorShares Pure US Cannabis ETF$3.82+1.33%$764.3M
MJETFMG Alternative Harvest ETF$24.79+0.74%$123.1M
CNBSAmplify Seymour Cannabis ETF$23.50+1.95%$77.3M
THCXCannabis ETF$16.60-0.26%$33.2M
YOLOAdvisorShares Pure Cannabis ETF$2.83-4.88%$33.1M
HMLSFGlobal X Marijuana Life Sciences ETF$5.210.00%$26.1M
WEEDRoundhill Cannabis ETF$16.36+0.15%$7.8M

Top Matchups by Market Cap

Companies closest to Cambria Cannabis ETF in market capitalization — the most meaningful head-to-head comparisons.

GWAYFLP

Greenway Greenhouse Cannabis

MCap: $15.3M

$0.12-3.62%
Compare
ROMJFLP

Rubicon Organics

MCap: $17.2M

$0.35+0.22%
Compare
CBSTFMSO

The Cannabist Company

MCap: $14.6M

$0.03+4.29%
Compare
VVIVFLP

Vivo Cannabis

MCap: $17.7M

$0.110.00%
Compare
MTLNFLP

MTL Cannabis Corp

MCap: $14.3M

$0.390.00%
Compare

Cross-Sector Comparisons

Top cannabis companies outside the ETF sector. Compare across different business models and market segments.

JAZZBiotech

Jazz Pharmaceuticals

MCap: $10.99B

$178.55-1.66%
Compare
SMGAncillary

Scotts Miracle-Gro

MCap: $3.54B

$60.96+0.96%
Compare
CURLFMSO

Curaleaf Holdings

MCap: $1.80B

$2.36+2.83%
Compare
TPBAncillary

Turning Point Brands

MCap: $1.73B

$90.62+0.69%
Compare
GTBIFMSO

Green Thumb Industries

MCap: $1.54B

$6.56+7.01%
Compare

Comparing TOKE in the Cannabis Market

Cambria Cannabis ETF (TOKE) is a ETF-sector cannabis company trading at $5.42 per share with a market capitalization of $16.0M. Among its ETF peers, TOKE ranks #7 by market cap, with trailing twelve-month revenue of $0 and a gross margin of 0.0%. The stock has moved 0.00% in the current session, trading on the NYSE exchange.

When comparing TOKE against other cannabis stocks, investors should consider key financial metrics including price-to-sales ratio (N/A), revenue growth (0.00% YoY), and balance sheet strength (cash of $0 vs. debt of $0). The comparison tables above allow you to evaluate Cambria Cannabis ETF relative to 7 sector peers and leading companies across all cannabis sub-sectors, helping you identify which stocks offer better value, stronger growth, or more favorable risk profiles.

Frequently Asked Questions

How does TOKE compare to other ETF stocks?+
Cambria Cannabis ETF has a market cap of $16.0M, placing it among 8 companies in the ETF sector. Its price-to-sales ratio is N/A and its gross margin is 0.0%. Use the table above to compare these metrics against every ETF peer.
What is TOKE's biggest competitor?+
By market capitalization, the closest comparable company is Greenway Greenhouse Cannabis (GWAYF) with a market cap of $15.3M. Click the compare link to view a full head-to-head analysis.
Is TOKE overvalued compared to its peers?+
Cambria Cannabis ETF trades at a P/S ratio of N/A. Compare this to sector peers in the table above to determine relative valuation. A lower P/S may indicate relative value, while a higher P/S may reflect growth expectations.
Which cannabis stock has better margins than TOKE?+
Cambria Cannabis ETF has a gross margin of 0.0%. Among its ETF peers, 0 companies report higher gross margins. See the Sector Peers table for a full ranking.
Can I compare TOKE to stocks in other cannabis sectors?+
Yes. The Cross-Sector Comparisons section above features top companies from sectors outside ETF. You can click any company to see a full side-by-side comparison with TOKE covering price, valuation, financials, and growth metrics.

Related Pages

Disclaimer: The comparison data on this page is for informational purposes only and does not constitute financial advice, investment recommendations, or an endorsement of any security. Cannabis stocks are highly volatile and subject to unique regulatory risks. Always conduct your own research and consult a licensed financial advisor before making investment decisions.Cannabismarketcap does not guarantee the accuracy or completeness of any data presented.